{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-107632","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.338026+00:00","generated_at":"2026-05-29T04:45:28.788842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rafael Holdings Q1 FY2025 net loss $9.0M; Cyclo merger on track","bullets":["Net loss attributable to Rafael Holdings of $9.0M ($0.37 per share) vs $3.6M loss a year ago.","Cash, cash equivalents and marketable securities of $54.3M as of October 31, 2024.","Pending merger with Cyclo Therapeutics (CYTH) expected to close in Q1 2025 after shareholder vote.","Cyclo Therapeutics' Phase 3 study for Trappsol Cyclo fully enrolled; interim results mid-2025.","R&D expenses $1.3M (up from $0.5M) on consolidation of Cornerstone and Day Three."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-107632","json":"https://secwatch.observer/filing/0001213900-24-107632.json","markdown":"https://secwatch.observer/filing/0001213900-24-107632.md","text":"https://secwatch.observer/filing/0001213900-24-107632.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024107632/0001213900-24-107632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024107632/ea0224341-8k_rafael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:45:28.788842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}